A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond.

CRISPR-mediated synthetic biology Machine learning Metabolic engineering Psilocybe Psilocybin Psychedelics Tryptamine

Journal

Biotechnology advances
ISSN: 1873-1899
Titre abrégé: Biotechnol Adv
Pays: England
ID NLM: 8403708

Informations de publication

Date de publication:
12 2023
Historique:
received: 06 04 2023
revised: 29 08 2023
accepted: 29 08 2023
medline: 20 11 2023
pubmed: 3 9 2023
entrez: 2 9 2023
Statut: ppublish

Résumé

Psychedelic mushrooms containing psilocybin and related tryptamines have long been used for ethnomycological purposes, but emerging evidence points to the potential therapeutic value of these mushrooms to address modern neurological, psychiatric health, and related disorders. As a result, psilocybin containing mushrooms represent a re-emerging frontier for mycological, biochemical, neuroscience, and pharmacology research. This work presents crucial information related to traditional use of psychedelic mushrooms, as well as research trends and knowledge gaps related to their diversity and distribution, technologies for quantification of tryptamines and other tryptophan-derived metabolites, as well as biosynthetic mechanisms for their production within mushrooms. In addition, we explore the current state of knowledge for how psilocybin and related tryptamines are metabolized in humans and their pharmacological effects, including beneficial and hazardous human health implications. Finally, we describe opportunities and challenges for investigating the production of psychedelic mushrooms and metabolic engineering approaches to alter secondary metabolite profiles using biotechnology integrated with machine learning. Ultimately, this critical review of all aspects related to psychedelic mushrooms represents a roadmap for future research efforts that will pave the way to new applications and refined protocols.

Identifiants

pubmed: 37659744
pii: S0734-9750(23)00154-4
doi: 10.1016/j.biotechadv.2023.108247
pii:
doi:

Substances chimiques

Hallucinogens 0
Psilocybin 2RV7212BP0
Tryptamines 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108247

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that we have no conflict of interest.

Auteurs

Marco Pepe (M)

Department of Plant Agriculture, University of Guelph, Ontario N1G 2W1, Guelph, Canada.

Mohsen Hesami (M)

Department of Plant Agriculture, University of Guelph, Ontario N1G 2W1, Guelph, Canada.

Karla A de la Cerda (KA)

School of Environmental Sciences, University of Guelph, Ontario N1G 2W1, Guelph, Canada.

Melissa L Perreault (ML)

Departments of Biomedical Sciences, University of Guelph, Guelph, Ontario, Canada.

Tom Hsiang (T)

School of Environmental Sciences, University of Guelph, Ontario N1G 2W1, Guelph, Canada.

Andrew Maxwell Phineas Jones (AMP)

Department of Plant Agriculture, University of Guelph, Ontario N1G 2W1, Guelph, Canada. Electronic address: amjones@uoguelph.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH